Search Results for 'glaukos corporation'
-
Contract Manufacturing | Materials | R&D & Design
Delivering the Goods: The Evolving World of Combination Products
This extremely diverse market fosters relationships between medical device and pharmaceutical companies.Sam Brusco, Associate Editor 11.04.19
-
Glaukos and Intratus Inc. Forge Global Licensing Agreement
Includes lead candidate for treatment of dry eye disease with potential future candidates for other corneal disorders and glaucoma.Business Wire 09.13.19
-
Contract Manufacturing
Glaukos Corporation to Acquire DOSE Medical Corporation
DOSE Medical will become a wholly owned subsidiary of Glaukos.Business Wire 06.20.19
-
Glaukos CEO Joins Avedro’s Board of Directors
Newest addition has more than 25 years of direct ophthalmic management experience.Business Wire 09.06.18
-
Study: Glaukos iStent Trabecular Micro-Bypass Stent Reduces IOP, Lowers Medication Burden
Combined with cataract surgery, iStent achieved a 28 percent reduction in mean medication use.Business Wire 03.01.18
-
Glaukos Corporation’s iDose Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile
Company prepares to commence Phase III U.S. IND Study in the first half of 2018.Business Wire 02.08.18
-
Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System
Three-stent device is designed to reduce IOP in refractory glaucoma patients.Business Wire 01.29.18
-
Glaukos to Begin Randomized U.S. IDE Pivotal Clinical Trial for the iStent SA System
Trial will enroll Pseudophakic Glaucoma subjects to assess the device’s safety, efficacy for reducing elevated IOP.Business Wire 01.22.18
-
Glaukos Issued New U.S. Patent
Latest patent covers ocular devices and methods of surgically implanting them.Business Wire 01.03.18
-
Study Reveals Potential Cost Efficiency of Using Glaukos iStent to Treat Elevated IOP
Data show cumulative cost at five years was lowest for two-stent procedure compared to laser treatment or topical medication.Business Wire 06.06.17
-
Study Shows Two Glaukos Micro-Bypass Stents, Topical Medication Reduce Intraocular Pressure
Data indicate 86 percent of eyes had an IOP of less than 18 mm Hg three years after the procedure.Business Wire 04.20.17
-
Surgical
Glaukos Corporation Acquires DOSE Medical's IOP Sensor System
Expected to complement the Glaukos pipeline of micro-scale glaucoma devices and drug-delivery systems.Business Wire 04.13.17
-
Neurological
Glaukos Corporation Hires Chief Medical Officer
Newest executive has been an investigator for various glaucoma clinical trials.Business Wire 03.02.17
-
Glaukos Hires Chief Financial Officer/Senior Vice President of Corporate Development
Former J.P. Morgan Healthcare investment banking veteran to join Glaukos in May.Business Wire 02.10.17
-
Contract Manufacturing
Glaukos Corporation Promotes Chief Commercial Officer to COO
Candidate has been with the company since 2008.Business Wire 02.08.17
-
Study Evaluates a Single Glaukos iStent Trabecular Micro-Bypass Stent as a Standalone Procedure
Case series of 42 pseudophakic eyes shows mean medicated intraocular pressure fecrease of 6.64 mm Hg.Business Wire 12.14.16
-
Glaukos Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patients
Clinical study shows mean IOP of 12.9 mm Hg and 61 percent reduction in mean medication burden.Business Wire 11.11.16
-
Study Shows Favorable Three-Year Results of Two Glaukos iStent Trabecular Micro-Bypass Stents
Patients who received two iStents achieved 43 percent reduction in mean intraocular pressure.Business Wire 09.29.16
-
Glaukos iStent Trabecular Micro-Bypass Stent Approved in Japan
Approved by the MHLW for use in combination with cataract surgery.Glaukos Corporation 03.30.16
-
Glaukos Reports Initial Results of Cataract Surgery Trial
iStent trabecular micro-bypass stent reduces intraocular pressure, medication need.Glaukos Corporation 01.20.16
-
Glaukos Will Begin Phase II Clinical Trial for Intraocular Implant
Trial will assess implant’s safety and preliminary efficacy for reduction of elevated intraocular pressure.Glaukos Corporation 01.08.16
